Related Experiment Videos
Correction of disease-causing CBS mutations in yeast
1Division of Population Sciences, Fox Chase Cancer Center, Philadelphia, Pennsylvania 19111, USA.
Nature Genetics
|May 20, 1998
Summary
A new study reveals that most homocystinuria mutations don't damage the enzyme's core but hinder its activation. This finding suggests novel therapeutic targets for homocystinuria and related vascular diseases.
Area of Science:
- Biochemistry
- Genetics
- Molecular Biology
Background:
- Mutations in cystathionine beta-synthase (CBS) cause homocystinuria, leading to high plasma homocysteine (tHcy) and thromboembolism.
- Elevated tHcy is a risk factor for vascular disease, linked to CBS gene variations.
Purpose of the Study:
- Investigate the functional impact of CBS mutations on enzyme activity.
- Identify potential therapeutic strategies for homocystinuria and associated vascular conditions.
Main Methods:
- Utilized a yeast expression system to study the effects of a CBS mutation lacking the C-terminal 145 amino acids.
- Assessed the functional suppression of various homocystinuric CBS mutant alleles.
Main Results:
- A CBS mutation deleting the C-terminal 145 amino acids suppressed the phenotype of several homocystinuric mutant alleles in yeast.
- The C-terminal domain inhibits CBS activity and is regulated by S-adenosylmethionine (AdoMet).
- Most homocystinuria mutations interfere with enzyme activation rather than catalytic domain function.
Conclusions:
- Homocystinuria mutations primarily affect CBS enzyme activation, not catalytic function.
- The C-terminal inhibitory domain presents a potential drug target for treating homocystinuria and homocysteine-related vascular disease.